Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up).
Anti-VEGF therapy
Choroidal thickness
Macular neovascularization
Neovascular age-related macular degeneration
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
21 Oct 2023
21 Oct 2023
Historique:
received:
13
08
2023
accepted:
09
10
2023
revised:
29
09
2023
medline:
21
10
2023
pubmed:
21
10
2023
entrez:
21
10
2023
Statut:
aheadofprint
Résumé
To evaluate the long-term choroidal thickness changes in combination with other morphological and functional outcomes during anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD) based on the subtype of macular neovascularization (MNV): MNV-1 (within the subretinal pigment epithelium space) and MNV-2 (within the subretinal space). This retrospective study included 58 eyes from 53 patients with naïve nAMD who received anti-VEGF therapy over a 60-month period. All eyes were treated initially with intravitreal bevacizumab following Pro re nata regimen. Main outcome measures included the following: subfoveal choroidal thickness (SFCT), best corrected visual acuity (BCVA), central macular thickness (CMT), development of subfoveal geographic atrophy (GA), and the number of injections. Thirty-four eyes had MNV-1 (group 1) and 24 eyes had MNV-2 (group 2). SFCT in group 1 vs group 2 was (210 ± 45 µm vs 191 ± 52 µm, p = 0.01) before treatment and (170 ± 47 µm vs 179 ± 48 µm, p = 0.24) after 60 months. BCVA (log MAR) in group 1 vs group 2 was (0.57 ± 0.18 vs 0.53 ± 0.22, p = 0.47) before treatment and (0.59 ± 0.23 vs 0.69 ± 0.16, p = 0.04) after 60 months. CMT in group 1 vs group 2 was (398 ± 154 µm vs 382 ± 103 µm, p = 0.86) before treatment and (297 ± 68 µm vs 283 ± 67 µm, p = 0.14) after 60 months. The number of injections per eye over a period of 60 months was significantly higher in group 1 (34.9 ± 11 vs 29.0 ± 14, p = 0.04). The proportion of eyes with subfoveal GA after 60 months was significantly higher in group 2 (13 eyes, 54%) than in group 1 (9 eyes, 25%) (p = 0.03). Over the full 60 months of anti-VEGF treatment, eyes with MNV-1 showed a greater reduction in choroidal thickness, better visual acuity, and less development of subfoveal geographic atrophy compared with eyes with MNV-2. The significantly thicker choroid in eyes with MNV type 1 at baseline seems to have a positive impact on long-term outcomes.
Identifiants
pubmed: 37864635
doi: 10.1007/s00417-023-06278-9
pii: 10.1007/s00417-023-06278-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Jonas JB, Cheung CMG, Panda-Jonas S (2017) Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol 6(6):493–497. https://doi.org/10.22608/APO.2017251
doi: 10.22608/APO.2017251
Augustin AJ, Kirchhof J (2009) Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets 13(6):641–651. https://doi.org/10.1517/14728220902942322
doi: 10.1517/14728220902942322
pubmed: 19456269
Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G (2020) Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev 5(5):CD012208. https://doi.org/10.1002/14651858.CD012208.pub2
doi: 10.1002/14651858.CD012208.pub2
pubmed: 32374423
Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F (2009) A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 247(1):1–11. https://doi.org/10.1007/s00417-008-0952-y
doi: 10.1007/s00417-008-0952-y
pubmed: 18843500
Gass JD (1994) Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Trans Am Ophthalmol Soc 92:91–111 (discussion 111-6)
pubmed: 7533960
pmcid: 1298502
Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30(9):1333–1349. https://doi.org/10.1097/IAE.0b013e3181e7976b
doi: 10.1097/IAE.0b013e3181e7976b
pubmed: 20924258
Mathis T, Holz FG, Sivaprasad S, Yoon YH, Eter N, Chen LJ, Koh A, Cunha de Souza E, Staurenghi G (2023) Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye (Lond) 37(9):1758–1765. https://doi.org/10.1038/s41433-022-02231-y
doi: 10.1038/s41433-022-02231-y
pubmed: 36104522
Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127(5):616–636. https://doi.org/10.1016/j.ophtha.2019.11.004
doi: 10.1016/j.ophtha.2019.11.004
pubmed: 31864668
Giovannini A, Mariotti C, Ripa E, Scassellati B, Tittarelli R (1994) Choroidal filling in age-related macular degeneration: indocyanine green angiographic findings. Ophthalmologica 208(4):185–191. https://doi.org/10.1159/000310483
doi: 10.1159/000310483
pubmed: 7526309
Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, Sekiryu T, Okada AA, Iida T (2015) Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 159(4):627–633. https://doi.org/10.1016/j.ajo.2014.12.025
doi: 10.1016/j.ajo.2014.12.025
pubmed: 25555799
Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S (2012) Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119(8):1621–1627. https://doi.org/10.1016/j.ophtha.2012.02.022
doi: 10.1016/j.ophtha.2012.02.022
pubmed: 22551738
Ellabban AA, Tsujikawa A, Ogino K, Ooto S, Yamashiro K, Oishi A, Yoshimura N (2012) Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 6:837–844. https://doi.org/10.2147/OPTH.S30907
doi: 10.2147/OPTH.S30907
pubmed: 22701085
pmcid: 3373228
Ogasawara M, Maruko I, Sugano Y, Ojima A, Sekiryu T, Iida T (2012) Retinal and choroidal thickness changes following intravitreal ranibizumab injection for exudative age-related macular degeneration. Nippon Ganka Gakkai Zasshi 116(7):643–649
pubmed: 22844783
Abdin AD, Suffo S, Bischoff-Jung M, Daas L, Pattmöller M, Seitz B (2020) Advantages of a designated IVI center for a German university eye hospital. Ophthalmologe 117(1):50–57. https://doi.org/10.1007/s00347-019-0911-5
doi: 10.1007/s00347-019-0911-5
pubmed: 31098660
Serra R, Coscas F, Cabral D et al (2022) Polypoidal choroidal neovascularization versus Type 1 choroidal neovascularization in age-related macular degeneration: a fractal analysis study. Retina 42(6):1005–1011
doi: 10.1097/IAE.0000000000003439
pubmed: 35594074
pmcid: 9112963
Chae B, Jung JJ, Mrejen S, Gallego-Pinazo R, Yannuzzi NA, Patel SN, Chen CY, Marsiglia M, Boddu S, Freund KB (2015) Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci 6(9):5040–5047. https://doi.org/10.1167/iovs.15-1649
doi: 10.1167/iovs.15-1649
Mrejen S, Jung JJ, Chen C, Patel SN, Gallego-Pinazo R, Yannuzzi N, Xu L, Marsiglia M, Boddu S, Freund KB (2015) Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med 4(7):1380–1402. https://doi.org/10.3390/jcm4071380
doi: 10.3390/jcm4071380
pubmed: 26239682
pmcid: 4519796
Abdin AD, Aljundi W, El Jawhari K, Suffo S, Weinstein I, Seitz B (2022) First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration. Front Pharmacol 13:860784. https://doi.org/10.3389/fphar.2022.860784
doi: 10.3389/fphar.2022.860784
pubmed: 35721125
pmcid: 9197757
Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 10:1857–1867
pubmed: 27330279
pmcid: 4898027
Lee CS, Kim AJ, Baughman D et al (2018) Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained. Retina 38(5):951–956
doi: 10.1097/IAE.0000000000001637
pubmed: 28406859
pmcid: 5636644
Empeslidis T, Storey M, Giannopoulos T, Konidaris V, Tranos PG, Panagiotou ES, Voudouragkaki IC, Konstas AG (2019) How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview. Adv Ther 36(7):1532–1548. https://doi.org/10.1007/s12325-019-00971-0
doi: 10.1007/s12325-019-00971-0
pubmed: 31102206
pmcid: 6824395
Wallsh JO, Gallemore RP (2021) Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells 10(5):1049
doi: 10.3390/cells10051049
pubmed: 33946803
pmcid: 8145407
Gale RP, Pearce I, Eter N et al (2020) Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol 104(4):493–499
doi: 10.1136/bjophthalmol-2019-314251
pubmed: 31383649
Kiss S, Campbell J, Almony A, Shih V, Serbin M, LaPrise A, Wykoff CC (2020) Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records. Ophthalmology 127(9):1179–1188. https://doi.org/10.1016/j.ophtha.2020.02.027
doi: 10.1016/j.ophtha.2020.02.027
pubmed: 32345477
Siktberg J, Kim SJ, Sternberg P Jr, Patel S (2023) Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration. Eye (Lond) 37(9):1844–1849. https://doi.org/10.1038/s41433-022-02253-6
doi: 10.1038/s41433-022-02253-6
pubmed: 36127425
Invernizzi A, Nguyen V, Teo K, Barthelmes D, Fung A, Vincent A, Gillies M (2019) Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project. Am J Ophthalmol 204:105–112. https://doi.org/10.1016/j.ajo.2019.03.001
doi: 10.1016/j.ajo.2019.03.001
pubmed: 30862501
Abdin AD, Devenijn M, Fulga R, Langenbucher A, Seitz B, Kaymak H (2023) Prevalence of geographic atrophy in advanced age-related macular degeneration (AMD) in daily practice. J Clin Med 12(14):4862. https://doi.org/10.3390/jcm12144862
doi: 10.3390/jcm12144862
pubmed: 37510977
pmcid: 10381805
Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ (2018) Macular atrophy in the HARBOR Study for neovascular age-related macular degeneration. Ophthalmology 125(6):878–886. https://doi.org/10.1016/j.ophtha.2017.12.026
doi: 10.1016/j.ophtha.2017.12.026
pubmed: 29477692
Chung SE, Kang SW, Lee JH, Kim YT (2011) Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118(5):840–845. https://doi.org/10.1016/j.ophtha.2010.09.012
doi: 10.1016/j.ophtha.2010.09.012
pubmed: 21211846
Ting DS, Ng WY, Ng SR, Tan SP, Yeo IY, Mathur R, Chan CM, Tan AC, Tan GS, Wong TY, Cheung CM (2016) Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Am J Ophthalmol 164:128–36.e1. https://doi.org/10.1016/j.ajo.2015.12.024
doi: 10.1016/j.ajo.2015.12.024
pubmed: 26743619
Inan S, Baysal Z, Inan UU (2019) Long-term changes in submacular choroidal thickness after intravitreal ranibizumab therapy for neovascular age-related macular degeneration: 14-mo follow-up. Curr Eye Res 44(8):908–915. https://doi.org/10.1080/02713683.2019.1600195
doi: 10.1080/02713683.2019.1600195
pubmed: 30909756
Rahman W, Chen FK, Yeoh J, da Cruz L (2013) Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients. Graefes Arch Clin Exp Ophthalmol 251(6):1483–1488. https://doi.org/10.1007/s00417-012-2199-x
doi: 10.1007/s00417-012-2199-x
pubmed: 23160538
Ünlü C, Erdogan G, Onal Gunay B, Sezgin Akcay BI, Kardes E (2015) Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for neovascular age-related macular degeneration. Int J Ophthalmol 8(4):849–851. https://doi.org/10.3980/j.issn.2222-3959.2015.04.38
doi: 10.3980/j.issn.2222-3959.2015.04.38
pubmed: 26309892
pmcid: 4539626
Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26(3):262–269. https://doi.org/10.1097/00006982-200603000-00002
doi: 10.1097/00006982-200603000-00002
pubmed: 16508424
Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85(4):425–430. https://doi.org/10.1016/j.exer.2007.05.008
doi: 10.1016/j.exer.2007.05.008
pubmed: 17714704
Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274(3):H1054–H1058. https://doi.org/10.1152/ajpheart.1998.274.3.H1054
doi: 10.1152/ajpheart.1998.274.3.H1054
pubmed: 9530221
Grossniklaus HE, Green WR (2004) Choroidal neovascularization. Am J Ophthalmol 137(3):496–503. https://doi.org/10.1016/j.ajo.2003.09.042
doi: 10.1016/j.ajo.2003.09.042
pubmed: 15013874
Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D (2018) Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti–vascular endothelial growth factor therapy: an optical coherence tomographic angiography analysis. Retina 38(7):1276–1288. https://doi.org/10.1097/IAE.0000000000001766
doi: 10.1097/IAE.0000000000001766
pubmed: 28723848
Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC (2014) Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol 157(5):1013–1021. https://doi.org/10.1016/j.ajo.2014.01.019
doi: 10.1016/j.ajo.2014.01.019
pubmed: 24487050
Sadda SR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, Gune S, Balasubramanian S (2020) Spectral-domain OCT analysis of risk factors for macular atrophy development in the HARBOR Study for neovascular age-related macular degeneration. Ophthalmology 127(10):1360–1370. https://doi.org/10.1016/j.ophtha.2020.03.031
doi: 10.1016/j.ophtha.2020.03.031
pubmed: 32402555